Ruoying Yu (Jifeng Feng)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 11

Top Venues

Cancer medicine

Clinical and translational medicine

Molecular oncology

OncoTargets and therapy

Geneseeq Technology Inc

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Geneseeq Technology Inc

Canada

Project Manager :: R&D

Publications

Jun Pu, Huannan Guo, Ruoying Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Sanyuan Tang, Qingyong Chang
Pan-cancer molecular analysis of EGFR large fragment deletion in the Asian population. Cancer medicine (2023)
Meifu Gan, Chen Zhang, Liqing Qiu, Yue Wang, Hua Bao, Ruoying Yu, Rui Liu, Xue Wu, Yang Shao, Peifeng Hou, Zhenglei Fei
Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients. Cancer medicine 11 (21) (2022)
Xiaojing Lai, Ruoying Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Yang Li, Ying Zhang, Qingqing Ding
Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population. Cancer medicine (2022)
Yong Da, Ge Shen, Ming Zhou, Tao Wang, Dapeng Dong, Lina Bu, Yun Shao, Qiyun Sun, Ruoying Yu
Rapid subcutaneous progression after immunotherapy in pretreated patients with metastatic carcinoma: two case reports. The Journal of international medical research 50 (4) (2022)
Naixin Liang, Zhongxing Bing, Yadong Wang, Xinyu Liu, Chao Guo, Lei Cao, Yuan Xu, Yang Song, Chao Gao, Zhenhuan Tian, Pancheng Wu, Jianchao Xue, Bowen Li, Ziqi Jia, Xiaoying Yang, Yijun Wu, Ruoying Yu, Rui Liu, Xiaoxi Chen, Qiuxiang Ou, Hua Bao, Xue Wu, Zhili Cao, Ji Li, Shanqing Li
Clinical implications of EGFR-associated MAPK/ERK pathway in multiple primary lung cancer. Clinical and translational medicine 12 (5) (2022)
Alei Feng, Ning Yang, Ruoying Yu, Jingwen Liu, Jiaohui Pang, Xue Wu, Yang Shao, Zhe Yang, Honghai Dai
Prognostic Implications of Six Altered Genes in Asian Non-Surgical Esophageal Carcinoma Patients Treated with Chemoradiotherapy. OncoTargets and therapy 15 (2022)
Lanxin Zhang, Siwen Sun, Xiaotian Zhao, Jingwen Liu, Yang Xu, Lingzhi Xu, Chen Song, Na Li, Jing Yu, Shanshan Zhao, Peiyao Yu, Fengqi Fang, Jiping Xie, Xuening Ji, Ruoying Yu, Qiuxiang Ou, Zuowei Zhao, Man Li
Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer. Molecular oncology 16 (20) (2022)
Xiaoxiao Wang, Yan Gao, Changguo Shan, Mingyao Lai, Haixia He, Bing Bai, Liqin Ping, Qixiang Rong, Ruyu Ai, Lei Wen, Zhaoming Zhou, Ruoying Yu, Qiuxiang Ou, Xue Wu, Xiaoxia Wang, Yang W Shao, Linbo Cai, Huiqiang Huang
Association of circulating tumor DNA from the cerebrospinal fluid with high-risk CNS involvement in patients with diffuse large B-cell lymphoma. Clinical and translational medicine 11 (1) (2021)
Yun Fan, Jinrong Qiu, Ruoying Yu, Ran Cao, Xiaoxi Chen, Qiuxiang Ou, Xue Wu, Yang W Shao, Misako Nagasaka, Jiexia Zhang, Sai-Hong Ignatius Ou
Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations. Molecular oncology 14 (8) (2020)
Bo Shen, Feixiang Wu, Jiazhou Ye, Rong Liang, Ruping Wang, Ruoying Yu, Xue Wu, Yang W Shao, Ruoying Yu
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors. Future oncology (London, England) 15 (22) (2019)
Zhanhong Chen, Tian Sun, Zi-Yan Yang, Yabing Zheng, Ruoying Yu, Xue Wu, Junrong Yan, Yang W Shao, Xiying Shao, Wen-Ming Cao, Xiao-Jia Wang
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Molecular genetics & genomic medicine 8 (2) (2019)

Ruoying Yu.css-eqlu8i{font-size:small;padding-left:4px;} (Jifeng Feng)

Publication Activity (10 Years)

Top Topics

Top Venues

Ruoying Yu (Jifeng Feng)